A major study published online in the England Journal of Medicine indicates that the value of a gene-activity test may allow many females with early-stage of breast cancer to skip chemotherapy without hurting their odds of beating the disease.
Advertisement
Oncotype DX is a gene test that can help clinicians provide their patients with the best treatment options for breast cancer in early stages by assessing the risk of cancer to recur and tumor to spread after surgery.
Instead, women would only need to take daily hormonal therapy medication for five to 10 years. “The results of this trial highlight the clinical utility of Oncotype DX and provide physicians and patients with greater confidence in using this test to make chemotherapy treatment decisions”.
They analyzed the heart function and the mental processes of 129 children aged 1 to 3 who were exposed prenatally to cancer treatment, and they found that their development was in no way impaired and the cancer drugs hadn’t affected their natural growth.
The trial used the Oncotype DX test on every patient to quantify individual risk of recurrence in order to assign them to treatment.
Recent studies, however, have shown that a test called Oncotype DX is proving remarkably effective.
But he warned: ‘Our data include many types of chemotherapy, but we can not guarantee that all types of chemotherapy are safe.
Results for the low risk patients were released after being given the hormone therapy and about 99 percent had not relapsed, 98 percent were alive, and 94 percent were free of invasive cancer.
Sparano was talking about a five-year study created to figure out if certain women could forgo chemotherapy without affecting their chances of recovery from breast cancer.
Pregnant women should not delay cancer treatment for it does not harm the fetus, a new study has found. Cancer treatment was previously delayed until the baby is born, a few were advised to deliver preterm or have an abortion. Others besides Oncotype DX also are on the market, and Hudis said he hopes the new study will encourage more, to compete on price and accuracy. In other words, going forward, a subset of women will not undergo the most grueling part of breast cancer treatment.
There are more than 2.8 million breast cancer survivors in the US. Maternal treatment should be administered immediately, as in the case of any other cancer patient, including chemotherapy.
Currently, Genomic Health has a Zacks Rank #3 (Hold). The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. Researchers then followed up with the babies more than a year after birth.
Advertisement
“The future is bright” for gene tests to more precisely guide treatment, he said. These forward-looking statements speak only as of the date hereof. In this regard, Genomic’s Oncotype DX Recurrence Score played a crucial role.
